Innate Pharma announces conference call and webcast for third quarter 2022 business update
Innate Pharma to present results from a preliminary analysis of the TELLOMAK Phase 2 trial in patients with advanced Sezary syndrome and ANKET platform at ASH 2022
Innate Pharma to participate in upcoming investor conferences
Innate Pharma 2023 financial calendar
Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced mycosis fungoides
Innate Pharma reports first half 2022 financial results and business update
Innate Pharma announces conference call and webcast for first half 2022 business update
Innate Pharma to present lacutamab PTCL Phase 1b design and ANKET platform at ESMO 2022
Innate Pharma to participate in upcoming investor conferences
Number of shares and voting rights of Innate Pharma as of august 1, 2022
